GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Net Change in Cash

Sensei Biotherapeutics (Sensei Biotherapeutics) Net Change in Cash : $2.85 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Sensei Biotherapeutics's Net Change in Cash for the three months ended in Mar. 2024 was $-2.06 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $2.85 Mil.

Sensei Biotherapeutics Net Change in Cash Historical Data

The historical data trend for Sensei Biotherapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Net Change in Cash Chart

Sensei Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial -0.40 16.35 -9.44 10.64 -4.78

Sensei Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.69 2.12 1.12 1.67 -2.06

Sensei Biotherapeutics Net Change in Cash Calculation

Sensei Biotherapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-32.023+38.412+-11.173+0
=-4.78

Sensei Biotherapeutics's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-7.616+5.77+-0.209+0
=-2.06

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensei Biotherapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics (Sensei Biotherapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Net Change in Cash
Comparable Companies
BIXT PLUR AIM NBIO CRBP AURX FRES INDP AGE ACST OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
407:Germany 407:Germany
Address
1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210
Website
https://www.senseibio.com
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.
Executives
Stephanie Krebs officer: Chief Business Officer C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi director, officer: President & CEO SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer director, 10 percent owner C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc 10 percent owner, other: See Remarks 228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p. other: See Explanation of Responses 340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward officer: Chief Scientific Officer C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c. 10 percent owner 340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher officer: Chief Business Officer 66 HAROLD ST, BOSTON MA 02119
William R Ringo director
Thomas G Ricks director H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce officer: Chief Scientific Officer C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer director C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English director C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850

Sensei Biotherapeutics (Sensei Biotherapeutics) Headlines

From GuruFocus

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

By sperokesalga sperokesalga • 04-20-2023

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

By Marketwired • 11-07-2023

Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody

By Value_Insider Value_Insider • 11-21-2022

Sensei Biotherapeutics Provides Update on Strategic Priorities

By Value_Insider Value_Insider • 12-08-2022

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo�

By Marketwired • 09-27-2023

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

By Marketwired • 09-13-2023

Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

By Stock market mentor Stock market mentor • 02-06-2023

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

By sperokesalga sperokesalga • 04-18-2023

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

By Marketwired • 10-23-2023

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

By sperokesalga sperokesalga • 03-21-2023